Many drugs have multiple indications which may offer commercial opportunities but also present strategic and operational challenges, such as different levels of investment, various layers of regulations and resource allocation.
In this case study, a mid-size biopharma (EBP) company developed a new oncology drug formulation but needed to prioritize an indication to achieve market approval. The company sought IQVIA's support to perform an independent assessment and select an indication which thereafter aligns with the company's decision.
IQVIA created a roadmap, incorporated data figures and tapped into their team of internal disease and biomedical experts, completing the evaluation in a shorter timeframe.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
